HIV and Hepatitis B: Unmasking the Risks and Protecting Your Health
"New research sheds light on the complexities of HIV/HBV co-infection, emphasizing the importance of long-term monitoring and tailored treatment strategies."
For individuals living with HIV, co-infection with Hepatitis B virus (HBV) presents a significant health challenge. While advancements in antiretroviral therapy (ART) have dramatically improved the lives of people with HIV, the impact of HBV co-infection on long-term health outcomes requires careful consideration. Recent research has begun to unravel the complexities of this co-infection, highlighting the need for ongoing monitoring and tailored treatment approaches.
Historically, studies on HIV and HBV co-infection have sometimes yielded conflicting results, particularly in resource-limited settings. Some studies have suggested that HBV co-infection increases the risk of liver-related complications and mortality among people with HIV, while others have found that HIV disease progression is the primary driver of mortality, overshadowing the impact of HBV.
The implementation of the "treat all" strategy for HIV infection in low-income countries marks a turning point. This initiative aims to provide immediate ART to everyone diagnosed with HIV, regardless of their CD4 count. As access to ART expands, the specific impact of HBV co-infection on clinical outcomes may become more evident, necessitating a deeper understanding of the interplay between these two viruses.
The Ongoing Burden of HIV and HBV
The WHO's Global hepatitis report 2026 warns that viral hepatitis remains a leading global health problem, despite the availability of an effective hepatitis B vaccine since the 1990s and effective antiviral treatments for chronic hepatitis B infection. WHO also provides updated global and regional HIV estimates, information on people receiving antiretroviral therapy, and progress toward international targets. In research on HIV and HBV, wider variation in HBV DNA was associated with higher baseline HIV RNA and higher baseline HBV DNA, while the study concluded that HBV activity is common among people with HBeAg-negative status and is partly linked to HIV replication.
Testing and Detection Strategies
CDC guidance recommends an opt-out approach to HIV testing to reduce stigma and encourage earlier diagnosis and treatment, and it advises testing all pregnant women as part of prenatal care. Laboratory methods for detecting HIV use different biological targets and can also be applied to monitor the efficacy of antiviral treatments. However, diagnosing HIV, HBV, and HCV in general-population settings remains challenging, which has led researchers to evaluate prediction tools for targeted testing. The BaroTest study is examining whether home self-sampling could expand current screening options if its acceptability and feasibility results are conclusive.
From Discovery to Prevention
The history of hepatitis-virus discovery has been described as a scientific adventure spanning the last 50 years, marked by cognitive milestones and breakthroughs that changed medicine and public health. The discovery of HBV helped initiate development of the hepatitis B vaccine, described as the first vaccine not prepared by tissue. Research on HBV's origins places the virus within an ancient family of hepatotropic DNA viruses dating back millions of years. HBV can cause acute and chronic disease, increasing the risk of cirrhosis and liver-cancer-associated mortality.
Decoding the Risks: What Factors Increase Mortality?
A recent study published in Clinical Infectious Diseases investigated the risk factors associated with one-year mortality among HIV-infected individuals, considering the impact of HBV co-infection. Using multivariable Cox proportional hazard regression analyses, the researchers identified several key factors that significantly influenced mortality rates. Notably, the study population consisted of individuals initiating ART, reflecting real-world clinical scenarios.
- Hepatitis B Surface Antigen (HBsAg) Positivity: Individuals who tested positive for HBsAg, indicating active HBV infection, had a higher risk of mortality compared to those who were HBsAg negative. This finding underscores the importance of screening for HBV co-infection in all people living with HIV.
- Advanced WHO Stage: Patients presenting with more advanced HIV disease (WHO stage 3 or 4) experienced significantly higher mortality rates than those in earlier stages (WHO stage 1 or 2). This highlights the critical role of early HIV diagnosis and treatment initiation.
- Low CD4 Cell Count: A CD4 cell count below 200 cells/µL was strongly associated with increased mortality. CD4 cells are crucial for immune function, and a low count indicates a weakened immune system, making individuals more vulnerable to opportunistic infections.
- Low Body Mass Index (BMI): A BMI below 18.5 kg/m², indicative of being underweight, was a significant predictor of mortality. Malnutrition can compromise immune function and overall health, increasing susceptibility to infections and other complications.
- Male Sex: Men had a higher risk of mortality compared to women in the study. This disparity may be related to differences in healthcare-seeking behavior, adherence to treatment, or biological factors.
Current Research Priorities
Recent research continues to examine the prevalence and burden of HBV-HIV comorbidity among adults living with HIV who receive antiretroviral therapy. A 2025 review searched Google Scholar, HINARI, EMBASE, Scopus, and PubMed to assess this burden. Other reviews address global HBV epidemiology, gaps in the HBV care cascade, and potential solutions for reaching hepatitis-related targets. Research on the two-dose HepB-CpG vaccine, also known as HEPLISAV-B, is exploring whether it may help address suboptimal immune responses to three-dose HepB-alum vaccines in people living with HIV.
Why Findings Can Depend on Follow-Up
Evidence about mortality differences in HIV-HBV coinfection can depend on the length of follow-up. A reply discussing two South African cohort studies reported that coinfected patients with high HBV replication had higher mortality than patients with HIV monoinfection when follow-up lasted 3 years, but not when it lasted 1.5 years. Separately, the Temprano randomized controlled trial analyzed the relationship between HBV replication, early antiretroviral therapy, and mortality in West African adults. The trial compared immediately initiating ART with deferring ART in HIV-infected adults with high CD4 counts.
The Future of HIV/HBV Research: Monitoring and Long-Term Strategies
As the "treat all" strategy for HIV becomes more widespread, it is crucial to monitor the long-term impact of HBV co-infection on clinical outcomes. Researchers emphasize the need for long-term data from cohorts with intensive retention strategies to better understand the interplay between HIV and HBV. This information will be vital for developing targeted interventions to improve the health and survival of individuals with HIV/HBV co-infection. Further research should focus on identifying the specific causes of mortality in co-infected individuals, including liver-related diseases and other complications. Ultimately, a comprehensive understanding of these factors will pave the way for more effective prevention, diagnosis, and treatment strategies, leading to improved health outcomes for people living with HIV and HBV.